Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...
There’s no better way to waste half an hour than with the best casual games. Whether it’s a pick-up-and-play puzzler, or an idle tycoon tap-a-thon, sometimes an easy time is a good time, and we have ...
Simply sign up to the Fashion myFT Digest -- delivered directly to your inbox. Last summer, I saw Stevie Nicks in concert for the first time. It was magical for many reasons: her anecdotal ...